Therapeutic chemokine receptor antagonists
CA 2322764 A1 · Owner: The University Of British Columbia · Inventors: Duronio, Vincent; Clark-Lewis, Ian; Gong, Jiang-Hong
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells treatment of an autoimmune , disease, treatment multiple sclerosis treatment of cancer, inhibition of , angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly the invention also , provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 12, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 12, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 12, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.